✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- DSIP = Delta Sleep-Inducing Peptide. Nonapeptide isolated in the 1970s from cerebral venous blood of sleep-deprived rabbits.
- Mechanism is sleep-phase modulation, not sedation. DSIP deepens slow-wave (delta) sleep when administered to subjects already entering sleep; does not initiate sleep in awake subjects.
- Research applications: sleep-architecture research, slow-wave-sleep-specific endpoints, chronic-pain-related sleep disturbance, circadian-rhythm research, alcohol-withdrawal sleep dysregulation.
- No benzodiazepine or melatonin-like activity — mechanistically distinct from any approved sleep medication.
- This guide covers the discovery history, mechanism, and where DSIP fits in sleep-research protocols.
DSIP Peptide: Delta Sleep-Inducing Peptide Research Guide
DSIP is the most-researched sleep-focused peptide in the CNS literature. The molecule was discovered in the 1970s by Schoenenberger and Monnier, who isolated it from the cerebral venous blood of sleep-deprived rabbits and showed that injecting it into awake recipient animals produced characteristic EEG changes consistent with deepened slow-wave sleep. The discovery established that endogenous peptide mediators of sleep biology exist — a concept that has continued to develop in modern neuroscience research.
What is DSIP
DSIP (CAS 62568-57-4) is a nonapeptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Molecular weight 848.8. The molecule was named for the EEG phenotype it produces — deepened delta-frequency (slow-wave) sleep — rather than for a specific receptor target (which remained uncharacterised for decades and is still incompletely understood compared with the kisspeptin or GLP-1 systems).
Mechanism: phase modulator, not sedative
The mechanism is the most important detail and the one most-commonly misunderstood: DSIP does not initiate sleep in awake subjects. The molecule’s effect is on the architecture of sleep that is already occurring — specifically deepening the slow-wave / delta phase of sleep that dominates the first 1-3 hours of typical sleep cycles. Administered to subjects already in or entering sleep, DSIP produces measurable EEG changes (increased delta-wave power, longer slow-wave-sleep duration); administered to awake subjects, DSIP does not produce sedation.
The distinction matters for research-protocol design. Sleep medications can broadly be divided into sleep initiators (benzodiazepines, Z-drugs, melatonin agonists), sleep maintainers (longer-acting versions of the above plus some antidepressants), and sleep architecture modulators (the category DSIP belongs to). Research scenarios studying slow-wave-sleep-specific endpoints, slow-wave-sleep-mediated cognitive consolidation, or sleep-architecture disruptions in disease models fit DSIP’s actual mechanism; protocols looking for a research-grade sleep initiator should look elsewhere.
Research applications
Most-published applications: sleep-architecture research (the classical use); slow-wave-sleep-specific endpoint studies (cognitive consolidation, memory research); chronic-pain-related sleep disturbance (where slow-wave-sleep fragmentation is the documented mechanism of pain-amplified sleep dysfunction); alcohol-withdrawal sleep dysregulation (DSIP has published research applicability here); circadian-rhythm research; and stress-related sleep-architecture disruption research models.
Research dosing
Published research protocols use 100-1000 mcg subcutaneous administration. Intranasal administration is also published but less common. The molecule is typically administered 30-60 minutes before intended sleep, allowing it to be present at the relevant CNS targets when sleep architecture is establishing.
Side-effect profile
Favourable. No documented sedation in awake subjects, no dependence liability, no cognitive impairment. The main consideration is that the mechanism is fundamentally different from standard sleep medications; research subjects expecting benzodiazepine-style sedation will not experience that effect and may interpret the absence as treatment failure rather than as the intended mechanism.
Comparator and stacking
Within the nootropic / CNS peptide cluster, DSIP is the sleep-architecture compound complementing Semax (cognitive) and Selank (anxiolytic). Combined research designs can pair DSIP with Selank for stress-related sleep dysfunction protocols. For broader CNS-cluster context see Best nootropic peptides.
Storage and reconstitution
Lyophilized vials at -20 °C long-term, 2-8 °C working stock. Reconstitute with bacteriostatic water. Reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.
Safety and regulatory status
DSIP has no FDA / EMA / MHRA approval. The research-grade compound is sold for in-vitro laboratory research and analytical reference use only. None of this constitutes medical advice for sleep applications.
FAQ
Will DSIP put me to sleep?
No — this is the most important mechanistic detail. DSIP does not initiate sleep in awake subjects. The molecule’s effect is on the architecture of sleep that is already occurring, specifically deepening the slow-wave / delta phase. Research subjects expecting benzodiazepine-style sedation will not experience that effect.
What does “delta sleep” actually mean?
Delta sleep is the EEG-frequency description of slow-wave sleep — the deepest stage of non-REM sleep, characterised by low-frequency (0.5-4 Hz) high-amplitude EEG waves. Delta sleep dominates the first 1-3 hours of typical sleep cycles and is the phase most associated with physical restoration, growth-hormone release, and cognitive consolidation of declarative memory.
What’s the typical research dose?
100-1000 mcg subcutaneous, 30-60 minutes before intended sleep. Intranasal administration is also published but less common.
Is DSIP a sleep initiator like melatonin?
No. Melatonin acts as a sleep initiator via the circadian / pineal system. DSIP acts as a sleep-architecture modulator. The two are mechanistically distinct and address different research questions — melatonin for circadian-rhythm research, DSIP for slow-wave-sleep architecture research.
Can DSIP be combined with other sleep medications?
Yes for research-protocol purposes. The mechanistic distinctness from benzodiazepines, Z-drugs, and melatonin agonists means DSIP’s slow-wave-sleep effects are additive to standard sleep initiators rather than redundant. Combined protocols use DSIP as the architecture-deepening arm alongside the chosen sleep-initiator arm.
Storage protocol?
Lyophilized at -20 °C long-term, 2-8 °C working; reconstituted at 2-8 °C use within 30 days; protect from light; never freeze-thaw.
Bottom line
DSIP is the most-researched sleep-architecture-modulating peptide. The molecule deepens slow-wave / delta-frequency sleep in subjects already entering sleep but does not initiate sleep in awake subjects. For sleep-architecture research, slow-wave-sleep-specific endpoint studies, and protocols studying the relationship between slow-wave sleep and cognitive consolidation or physical restoration, DSIP is the appropriate research-grade compound. Most-paired with Selank in protocols studying stress-related sleep dysfunction.
Related research guides
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.